Current Clinical Trials

Every treatment, medication, and procedure available today was once tested as part of a clinical trial. These carefully designed scientific studies are among the last steps in the research process, helping doctors continually improve care. The primary goal of clinical trials is to advance medicine by finding better ways to treat and prevent disease. Clinical trials are available through the Clinical Trials Office and McGlinn Cancer Institute.

We have several open clinical trials that can be reviewed below.

For cancer clinical trials, please visit the Cancer Clinical Trials page.

COVID-19

Observational

COVID-19 in Patients with HIV

Investigator: Debra Powell, MD

The purpose of his study is to characterize the clinical presentation and course of COVID-19 in patients with HIV.

Learn more about the COVID HIV trial [PDF] or call the Clinical Trials Office at 484-628-8585.

IMPACC

"Immunophenotyping Assessment in a COVID-19 COHORT"

Investigator: Debra Powell, MD

The purpose of this observational study is to describe the relationship between the body's immune responses and the severity of COVID-19 in patients.

Learn more about the IMPACC trial [PDF].

View on NIH.gov and ClinicalTrials.gov, or call the Clinical Trials Office at 484-628-8585 for more information.

Treatment

CAN-COVID

"Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants with COVID-19-induced Pneumonia"

Investigator: Debra Powell, MD

The purpose of this study is to to assess the efficacy and safety of canakinumab plus standard-of-care (SOC) compared with placebo plus SOC in patients with COVID-19-induced pneumonia and cytokine release syndrome (CRS). This study is closed to enrollment.

Learn more about the CAN-COVID trial [PDF].

View on Novartis.com and ClinicalTrials.gov, or call the Clinical Trials Office at 484-628-8585 for more information.

Convalescent Plasma

"Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19"

Investigator: Debra Powell, MD

The purpose of this treatment plan is to provide access to investigational convalescent plasma for patients in acute care facilities infected with COVID-19. Plasma will be obtained from donors with a documented diagnosis of COVID-19 that have recovered from the infection.

Learn more about the Convalescent Plasma treatment [PDF].

View on RedCrossBlood.org and USCOVIDPlasma.org, or call the Clinical Trials Office at 484-628-8585 for more information.

Cardiology

Acute Coronary Syndrome

AEGIS II

"Study to Investigate CSL112 in Subjects with Acute Coronary Syndrome (AEGIS II)"

Investigator: Earl Hope, MD

The purpose of this study is to evaluate the efficacy of CSL112 on reducing the risk of MACE (CV death, MI, or stroke) from the time of randomization through 90 days in subjects with ACS (diagnosed with STEMI or NSTEMI).

Learn more about the AEGIS II trial [PDF].

View on ClinicalTrials.gov or call the Clinical Trials Office at 484-628-8585 for more information.

Heart Failure

GUIDE-HF

"Hemodynamic-GUIDEd Management of Heart Failure"

Investigator: Jared Green, DO

The purpose of this study is to demonstrate the effectiveness of the CardioMEMS™ Heart Failure System in an expanded patient population, including patients with New York Heart Association (NYHA) Class II, III, or IV heart failure with or without a prior hospitalization.

Learn more about the GUIDE-HF trial [PDF].

View on ClinicalTrials.gov or call the Clinical Trials Office at 484-628-8585 for more information.

OPTIMIZER Smart

"OPTIMIZER Smart Post-Approval Study"

Investigator: Jared Green, DO

The purpose of this post approval study (PAS) is to evaluate the safety of the long-term use of the OPTIMIZER Smart device and Cardiac Contractility Modulation therapy on the quality of life and heart failure symptoms for patients who remain symptomatic despite optimized guideline directed heart failure medications.

Learn more about the OPTIMIZER Smart study [PDF].

View on ClinicalTrials.gov, Impulse-Dynamics.com, and FDA.gov or call the Clinical Trials Office at 484-628-8585 for more information.

REHAB-HF

"A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients"

Investigator: Jared Green, DO

The purpose of this study is to measure the effect of an exercising training program has on physical function, hospital readmission rates and medical costs for people admitted to the hospital with a diagnosis of heart failure. This study is closed to enrollment.

Learn more about the REHAB-HF trial [PDF].

View on ClinicalTrials.gov or call the Clinical Trials Office at 484-628-8585 for more information.

Endocrinology and Diabetes

Call the Clinical Trials Office at 484-628-8585 for information about any available studies.

ENT

Sleep Apnea

ADHERE

"Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International Registry (ADHERE Registry)"

The purpose of registry is to understand the effectiveness, use, and long term safety of the FDA-approved Inspire device within
clinical practice on post-implant patient outcomes such as improvement of Apnea Hypopnea Index and Epworth Sleepiness Scale.

Learn more about the ADHERE registry [PDF].

View on ClinicalTrials.gov, InspireSleep.com, and MayoClinic.org or call the Clinical Trials Office at 484-628-8585 for more information.

Infectious Disease

Babesiosis

Babesia Infection

Reading Hospital Investigator: Debra Powell, MD

The purpose of this study is to gather data for the development of a bedside rapid diagnostic test for the detection of Babesia microti infection.

Learn more about the Babesia Infection trial [PDF] or call the Clinical Trials Office at 484-628-8585 for more information.

Candidemia

ReSTORE

"Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis"

Investigator: Debra Powell, MD

The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by optional oral fluconazole).

Learn more about the ReSTORE trial [PDF].

View on ClincalTrials.gov or call the Clinical Trials Office at 484-628-8585 for more information.

Lyme Disease

SLICE

"Sex-based differences in the immunobiology and natural history of acute and convalescent Lyme disease"

Johns Hopkins Primary Investigator: John Aucott, MD

Reading Hospital Primary Investigator: Debra Powell, MD

The purpose of this study is to examine sex-based differences in immune response and clinical outcomes in participants with Lyme disease.

Learn more about the SLICE trials [PDF].

View the SLICE handout [PDF] or call the Clinical Trials Office at 484-628-8585 for more information.

Nephrology

Chronic Kidney Disease (CKD) & Anemia

ASCEND-NHQ

"Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat in Non-Dialysis participants evaluating Hemoglobin and Quality of life"

Investigator: Trudy Demko, MD

This study is designed to evaluate safety, efficacy and quality of life of daprodustat compared to placebo in non-dialysis subjects with anemia associated with chronic kidney disease. This study is closed to enrollment.

Learn more about the ASCEND-NHQ trial [PDF].

View on ClinicalTrials.gov or call the Clinical Trials Office at 484-628-8585 for more information.

ASCEND-ND

"Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat-Non-Dialysis"

Investigator: Trudy Demko, MD

This study is designed to compare the cardiovascular safety of daprodustat (study med) to darbepoetin alfa and the efficacy of these medications for maintaining hemoglobin levels.

Learn more about the ASCEND-ND trial [PDF].

View on ClinicalTrials.gov or call the Clinical Trials Office at 484-628-8585 for more information.

Neurology

Call the Clinical Trials Office at 484-628-8585 for information about any available studies.

Oncology

Colon Cancer Screening

Biofilm Epidemiology and Mechanisms of Colon Cancer

Johns Hopkins Primary Investigator: Cynthia Sears, MD

Reading Hospital Primary Investigator: Louis LaLuna, MD

This research is being done to learn more about why people get colon cancer. We are looking to identify specific bacteria in the colon that may be linked to the development of colon cancer, and small biopsies will be taken along with other samples to look for these bacteria. This study is closed to enrollment.

Learn more about the Biofilm trial [PDF].

View on Cancer.gov or call the Clinical Trials Office at 484-628-8585 for more information.

Lung Cancer Screening

Lung Cancer Biomarkers

"A Study to Evaluate a Panel of Blood Biomarkers for Use in Patients Undergoing Evaluation for Lung Cancer"

Investigator: Uday Dasika, MD

The purpose of this study is to develop a blood-based gene expression signature to be used in the detection of lung cancer in patients who underwent radiologic screening for lung cancer and had lung nodules detected.

Learn more about the Lung Cancer Biomarker trial [PDF] or call the Clinical Trials Office at 484-628-8585 for more information.

Weight Loss

Call the Clinical Trials Office at 484-628-8585 for information about any available studies.

Women's Health

Polycystic Ovary Syndrome (PCOS)

Elaris PCOS I

"Study of the Safety and Efficacy of Elagolix in Women with Polycystic Ovary Syndrome"

Investigator: Stephen Fehnel, MD

The study will assess the potential impact of Elagolix on disordered pituitary and ovarian hormones in women with Polycystic Ovary Syndrome (PCOS).

Learn more about the PCOS trial [PDF].

View on ClinicalTrials.gov or call the Clinical Trials Office at 484-628-8585 for more information.

Pregnancy

MATISSE

"A Phase 3 Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy"

Investigator: Mark Martens, MD

The study will assess the safety and efficacy of an RSV vaccine in pregnant women and infants.

Learn more about the MATISSE trial [PDF].

View on ClinicalTrials.gov or call the Clinical Trials Office at 484-628-8585 for more information.

Sterilization

POET

"Study to Assess Outcomes in Women Undergoing Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization"

Investigator: Stephen Fehnel, MD

This study is designed to assess post-procedural outcomes for women who chose to undergo either hysteroscopic sterilization (Essure®) or laparoscopic tubal sterilization. This study is closed to enrollment.

Learn more about the POET trial [PDF].

View on ClinicalTrials.gov or call the Clinical Trials Office at 484-628-8585 for more information.

Urinary Tract Infection (UTI)

EAGLE 2

"A Study of Evaluate the Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)"

Investigator: Stephen Fehnel, MD

This study will evaluate the therapeutic response of oral gepotidacin compared to oral nitrofurantoin for uncomplicated UTI in adolescent and adult female subjects. For this study, Reading Hospital will only be enrolling women >18 years.

Learn more about the EAGLE 2 trial [PDF].

View on ClinicalTrials.gov or call the Clinical Trials Office at 484-628-8585 for more information.